INMB — INmune Bio, Inc.
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 13
- Website: https://www.inmunebio.com
Latest SEC filings for INMB
- 3 — 2026-09-17
- 8-K — 2026-09-14
- 10-Q — 2026-08-06
- 8-K — 2026-07-31
- 8-K — 2026-07-01
- 8-K — 2026-06-23
- 8-K — 2026-06-17
- 8-K — 2026-06-02
- 8-K — 2026-05-14
- 10-Q — 2026-05-07
Latest INMB news
- — Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight (GlobeNewswire Inc.)
- — INmune Bio, Quantum Computing to collaborate on XPro Alzheimer's treatment (seekingalpha_market)
- — INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™
- — INmune Bio to Attend the 2026 Maxim Growth Summit (globenewswire.com)
Educational tool only — not investment advice.